A5077625963- Pancreatic and Hepatic Oncology Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Neuroendocrine Tumor Research Advances
- Cancer Genomics and Diagnostics
- Pancreatitis Pathology and Treatment
- Intraperitoneal and Appendiceal Malignancies
- Cancer Diagnosis and Treatment
- Liver Disease Diagnosis and Treatment
- COVID-19 and healthcare impacts
- Palliative Care and End-of-Life Issues
- Gastric Cancer Management and Outcomes
- Cancer, Lipids, and Metabolism
- Economic and Financial Impacts of Cancer
- Colorectal Cancer Screening and Detection
- Appendicitis Diagnosis and Management
- Cancer, Hypoxia, and Metabolism
- Liver physiology and pathology
- Cancer Immunotherapy and Biomarkers
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Traumatic Brain Injury and Neurovascular Disturbances
- Lung Cancer Research Studies
- Renal cell carcinoma treatment
- Ethics in Clinical Research
- Fibroblast Growth Factor Research
- Histone Deacetylase Inhibitors Research
Northwell Health
2020-2025
Hofstra University
2020-2025
North Shore Diabetes and Endocrine Associates
2024-2025
Donald & Barbara Zucker School of Medicine at Hofstra/Northwell
2021-2024
Long Island Jewish Medical Center
2022-2024
North Shore University Hospital
2024
Cancer Institute (WIA)
2024
Indiana University School of Medicine
2019-2021
Indiana University – Purdue University Indianapolis
2019-2021
University of North Carolina at Chapel Hill
2021
Hepatocellular carcinoma (HCC) is the most rapidly increasing cause of cancer-related mortality in United States. Because lack viable treatment options for HCC, prevention high-risk patients has been proposed as an alternative strategy. The main risk factor HCC cirrhosis and several lines evidence implicate epidermal growth (EGF) progression development HCC. We therefore examined effects EGF receptor (EGFR) inhibitor erlotinib on liver fibrogenesis hepatocellular transformation three...
Objective: To evaluate if patient-derived organoids (PDOs) may predict response to neoadjuvant (NAT) chemotherapy in patients with pancreatic adenocarcinoma. Background: PDOs have been explored as a biomarker of therapy and for personalized therapeutics cancer. Methods: During 2017–2021, were enrolled into an IRB-approved protocol PDO cultures established. interest analyzed through translational pipeline incorporating molecular profiling drug sensitivity testing. Results: One hundred...
Abstract Background Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) is a laparoscopic locoregional treatment for peritoneal metastases (PM) from colorectal cancer (CRC) or appendiceal (AC) in patients who cannot undergo cytoreductive surgery (CRS). While PIPAC has been studied Europe and Asia, it not investigated the USA. Patients Methods We evaluated with 90 mg/m 2 oxaliplatin alone (cycle 1) preceded by systemic fluorouracil (5-FU) leucovorin (LV) 2–3) as multicenter...
BACKGROUND Hepatocellular carcinoma (HCC)‐associated mortality is increasing at an alarming rate, and there a readily identifiable cohort of at‐risk patients with cirrhosis, viral hepatitis, nonalcoholic fatty liver disease, diabetes. These are candidates for chemoprevention. Metformin attractive agent chemoprevention because it inexpensive, has favorable safety profile, well tolerated over long time periods. METHODS The authors studied the efficacy metformin as prevention in clinically...
Platelet dysfunction following trauma has been identified as an independent predictor of mortality. We hypothesized that fresh frozen plasma (FFP) resuscitation would attenuate platelet compared with 0.9% normal saline (NS).Twelve swine were subjected to multisystem (traumatic brain injury, liver rib fracture, and soft tissue injury) hemorrhagic shock (40% estimated blood volume). Animals left in (mean arterial pressure, 30-35 mm Hg) for 2 hours followed by three times shed volume NS (n = 6)...
Objective: To assess the impact of a granular measure SED on pancreatic surgical and cancer-related outcomes at high-volume cancer center that employs standardized clinic pathway. Summary Background Data: Prior research has shown low socioeconomic status leads to less treatment worse for PDAC. However, these studies employed inconsistent definitions categorizations status, aggregated individual data using large geographic areas, lacked detailed clinicopathologic variables. Methods: We...
Objectives: Hemorrhagic shock (HS) can initiate an exaggerated systemic inflammatory response and multiple organ failure, especially if followed by a subsequent insult ("second hit"). We have recently shown that histone deacetylase inhibitors improve survival in rodent models of HS or septic shock, individually. In the present study, we examined whether valproic acid (VPA), inhibitor, could prolong "two-hit" model: from cecal ligation puncture (CLP). Methods: Male Sprague-Dawley rats...
A recent gene expression classification of hepatocellular carcinoma (HCC) includes a poor survival subclass termed S2 representing about one-third all HCC in clinical series. cells express E-cadherin and c-myc secrete AFP. As the fibroblast growth factor receptors (FGFRs) differs between non-S2 HCC, this study investigated whether molecular subclasses predict sensitivity to FGFR inhibition. cell lines were significantly more sensitive (p < 0.001) inhibitors BGJ398 AZD4547. decreased MAPK...
Abstract Background Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) is a novel, minimally invasive, safe, and repeatable method to treat carcinomatosis. Evidence regarding the clinical benefit (quality of life survival) PIPAC compared with that conventional standard therapy (ST) lacking. Methods This secondary analysis phase 1 US-PIPAC trial for refractory colorectal appendiceal A cohort was retrospective consecutive patients receiving ST. The primary outcome number good days...
Background/Objectives: Treatment options for advanced HCC are limited. Immunotherapy, a promising new therapeutic, has recently been incorporated as first-line systemic treatment. This study evaluates immunotherapy uptake and disparities in its adoption prior to approval, which currently unknown. Methods: Patients diagnosed with stage IV between 2014 2019 were identified the National Cancer Database (NCDB). Multivariable logistic regression analysis was performed demographic clinical...